Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Metabolic Outcomes Among Patients With Chronic Myelogenous Leukemia (CML) Initiating Therapy With a Tyrosine Kinase Inhibitor (TKI)

NCT02733445 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT02733445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02733445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Metabolic Outcomes Among Patients With Chronic Myelogenous Leukemia (CML) Initiating Therapy With a Tyrosine Kinase Inhibitor (TKI)
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
December 31, 2015
Completion date
March 31, 2016
Enrollment
2,650 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia (cml)